KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $73.6 million.

  • Travere Therapeutics' Invested Capital rose 9285.36% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 9285.36%. This contributed to the annual value of $127.8 million for FY2024, which is 3638.02% down from last year.
  • Per Travere Therapeutics' latest filing, its Invested Capital stood at $73.6 million for Q3 2025, which was up 9285.36% from $101.6 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Invested Capital ranged from a high of $362.7 million in Q1 2021 and a low of $15.1 million during Q2 2024
  • For the 5-year period, Travere Therapeutics' Invested Capital averaged around $167.4 million, with its median value being $127.8 million (2024).
  • In the last 5 years, Travere Therapeutics' Invested Capital crashed by 8772.38% in 2024 and then surged by 57066.09% in 2025.
  • Over the past 5 years, Travere Therapeutics' Invested Capital (Quarter) stood at $309.5 million in 2021, then crashed by 83.89% to $49.9 million in 2022, then skyrocketed by 302.82% to $200.8 million in 2023, then crashed by 36.38% to $127.8 million in 2024, then tumbled by 42.42% to $73.6 million in 2025.
  • Its Invested Capital was $73.6 million in Q3 2025, compared to $101.6 million in Q2 2025 and $101.6 million in Q1 2025.